Studies using tissue obtained at autopsy suggest that changes in cholinergic neurons could be important in the pathology of schizophrenia. 8 Given the relative concentrations of M 1 , M 2 and M 4 receptors in the human CP and the magnitude of the decreases in radioligand binding in schizophrenia, our results most likely reflected a change in the density of M 1 and M 2 receptors in the CP from the schizophrenic subjects. In situ hybridisation has now been used to determine levels of m1 and m2 mRNA in CP from 14 schizophrenic and 16 control subjects previously used for radioligand binding. m2 mRNA in the CP from the schizophrenic and control subjects was below the sensitivity of in situ hybridisation. There was no difference in the levels of m1 mRNA in CP from schizophrenic and control subjects (mean ± SEM: 103 ± 16 vs 106 ± 17 fmol [ We have used CP from schizophrenic and control studies to measure levels of m1 and m2 mRNA. There were no significant differences in the mean donor age (P = 0.77) or mean postmortem interval (PMI; P = 0.63; Table 1 ) between the schizophrenic and control group. However, the mean tissue pH was significantly lower for the tissue from the schizophrenic subjects (P Ͻ 0.05). There was no significant relationship between donor age (r = 0.12, P = 0.78 and r = −0.02, P = 0.96), tissue PMI (r = 0.10, P = 0.76 and 0.19, P = 0.45), tissue pH (r = 0.2, P = 0.17 and 0.09, 0.75), or duration of illness (DOI) (r = 0.03, 0.93) and levels of hybridised M 1 receptor oligonucleotide probe in the schizophrenic or control group respectively. This would suggest that these are not confounding factors in this study. Significantly, there was a correlation between final antipsychotic drug dose (FDD) and the level of M 1 receptor oligonucleotide probe hybridised to CP from the schizophrenic subjects (r = 0.62, P Ͻ 0.02; Figure 1 ).
whereas [
3 H]AF-DX 384 would mainly bind to muscarinic 2 (M 2 ) and M 4 receptors. 8 Given the relative concentrations of M 1 , M 2 and M 4 receptors in the human CP and the magnitude of the decreases in radioligand binding in schizophrenia, our results most likely reflected a change in the density of M 1 and M 2 receptors in the CP from the schizophrenic subjects. In situ hybridisation has now been used to determine levels of m1 and m2 mRNA in CP from 14 schizophrenic and 16 control subjects previously used for radioligand binding. m2 mRNA in the CP from the schizophrenic and control subjects was below the sensitivity of in situ hybridisation. There was no difference in the levels of m1 mRNA in CP from schizophrenic and control subjects (mean ± We have used CP from schizophrenic and control studies to measure levels of m1 and m2 mRNA. There were no significant differences in the mean donor age (P = 0.77) or mean postmortem interval (PMI; P = 0.63; Table 1 ) between the schizophrenic and control group. However, the mean tissue pH was significantly lower for the tissue from the schizophrenic subjects (P Ͻ 0.05). There was no significant relationship between donor age (r = 0.12, P = 0.78 and r = −0.02, P = 0.96), tissue PMI (r = 0.10, P = 0.76 and 0.19, P = 0.45), tissue pH (r = 0.2, P = 0.17 and 0.09, 0.75), or duration of illness (DOI) (r = 0.03, 0.93) and levels of hybridised M 1 receptor oligonucleotide probe in the schizophrenic or control group respectively. This would suggest that these are not confounding factors in this study. Significantly, there was a correlation between final antipsychotic drug dose (FDD) and the level of M 1 receptor oligonucleotide probe hybridised to CP from the schizophrenic subjects (r = 0.62, P Ͻ 0.02; Figure 1 ).
For the m1 and m2 radioactive oligonucleotide probes, levels of hybridised probe were low after RNAase treatment and in the presence of excess nonradioactive oligonucleotide probe. Where tissue was only exposed to radioactive m1 oligonucleotide probe, there was a significant increase in hybridised probe above that in the presence of excess non-radioactive probe. This was not the case for the m2 oligonucleotide probe, a finding consistent with the absence of cell bodies containing m2 mRNA within human CP. Significantly, radioligand binding studies suggest that there are significant levels of M 2 receptor in the human CP. 9 Together, these data would be consistent with the M 2 receptor being located on neurons that innervate the CP but which have their cell bodies outside that brain region. This in turn would add weight to the hypothesis that the M 2 receptor is primarily an autoreceptor 7 in human CP. There was no difference between the levels of hybridised m1 oligonucleotide probe in CP from schizophrenic and control subjects (P = 0.91, Table 1 ; Figure 2 ). Some caution must be applied when interpreting these data. The positive correlation between levels of hybridised m 1 oligonucleotide probe and final recorded dose of antipsychotic drug could indicate that the antipsychotic drugs had increased the levels of m 1 mRNA. Hence the lack of difference in levels of hybridised probe between the CP from the schizophrenic and controls could be due to antipsychotic drug treatment increasing initially low levels of mRNA in the CP from the schizophrenic subjects to levels seen in the control subjects. Whilst antipsychotic drugs have not yet been shown to affect the levels of muscarinic receptor mRNA, they have been shown to affect the level of expression of other molecules in the brain. For example, treating rats with antipsychotic drugs has been shown to differentially affect the expression of dopamine receptors 10 and increase the levels of mRNA encoding synaptophysin 11 and the neurotensin receptor. 12 Thus, it remains feasible that levels of mRNA for the M 1 receptor could be altered in the brains of sub- ).
jects with schizophrenia receiving even more complex drug treatments. However, the analysis of covariance of the data in this study would suggest that the relationship between final drug dose and levels of hybridisation has not significantly affected the between groups analysis. Using in situ radioligand binding and autoradiography we have previously reported a single point saturation analysis study that showed a significant decrease in [ 3 H]pirenzepine binding (15 nM; displaced by QNX: 10 −6 M) to CP from subjects with schizophrenia. 5 Moreover, this decrease in radioligand binding was most apparent in subjects treated with benztropine. In the present study, because mRNA is degraded at low pH, 13 tissue was only used from the subjects in our study of radioligand binding when the pH of their CP was greater than 6.0 (Table 1) . [ 3 H]pirenzepine binding in the CP from these subjects was still lower in the schizophrenic compared to the control subjects (197 ± 22 vs 292 ± 9.7 fmol mg −1 ETE; P Ͻ 0.001). However, [ 3 H]pirenzepine binding to CP from schizophrenic subjects treated with benztropine was not lower when com- pared to schizophrenic subjects not treated with benztropine (180 ± 34 vs 208 ± 31 fmol mg −1 ETE, P = 0.56). This raises the possibility that, in our earlier study, the apparent association between benztropine treatment and [ between radioligand binding and low pH. This is not a factor that has influenced data in the present study.
As previously suggested, under the conditions used in our experiments, [ 3 H]pirenzepine would predominately bind to the M 1 receptor. 7 Thus, our present data combined with data from our radioligand binding studies suggest there is only a poor correlation between levels of M 1 receptor and the mRNA for that receptor in CP from schizophrenic and control subjects (Figure 3 ).
In conclusion, findings from our studies of m2 mRNA in human CP would suggest that the M 2 receptor is likely to be predominantly an autoreceptor in that brain region. In addition, studies of the M 1 receptor suggest that there is a decrease in that receptor in the CP from schizophrenic subjects without an associated change in mRNA encoding that receptor. However, it remains to be determined whether the levels of m1 mRNA are increased by treatment with antipsychotic drugs, perhaps masking possible changes due to disease processes in schizophrenia. Even if that is the case our studies emphasise the difficulty in interpreting studies of mRNA at the level of expressed protein if some measure of that protein is not available.
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Methods and materials
Materials
Complementary oligonucleotide probes to the human m1 and m2 receptor gene, [
35 S]dATP (1200-1500 Ci mmol
) and oligonucleotide 3Ј-tail end labelling systems were purchased from New England Nuclear (Du Pont Australia Pty Ltd, Sydney, Australia). The oligonucleotide probes were 48mers which were complementary to bases 4-51, 722-768 and 811-858 of the Hm1 and 3-51, 681-728 and 781-828 of the Hm2 receptor mRNA. [ 14 C] microscales were obtained from Amersham Life Science, Amersham, Bucks, UK. Other chemicals were purchased from BDH Laboratory Supplies, Poole, Dorset, UK.
Tissue collection
Human CP was obtained at autopsy from the left brain hemisphere of 14 subjects with a provisional diagnosis of schizophrenia and 16 subjects with no clinical history of psychiatric illness or histopathological evidence of neurological disease (controls) ( Table 1) . CP from all subjects had been previously used for studies of radioligand binding to muscarinic receptors. 5 The provisional diagnoses of schizophrenia were confirmed according to DSM-III-R criteria following an extensive case review.
14,15 DOI was taken as the time from first hospital admission to death. A pharmacological history was also collected for all subjects who had schizophrenia. Tissue was collected from control subjects so that they were closely matched for age and PMI to schizophrenic subjects. PMI is the time between witnessed death and autopsy or, where death was not witnessed, the interval half way between the subject being last seen and being found, to autopsy. Tissue was only collected when this interval was less than 5 h. All cadavers were stored at 4°C within 5 h of death or discovery.
Once collected, the brain tissue was rapidly frozen and then stored at −70°C until required. The selection of tissue blocks was standardised for each subject using a set of standard landmarks. 16 Thus, coronal sections extended from the head of the caudate nucleus and putamen to the rostral edge of the anterior commissure.
In situ hybridization (ISHH)
Sections (20 m) of human CP were fixed with 4% paraformaldehyde in phosphate-buffered saline, pH 7.5 (PBS) for 5 min, dehydrated through ethanol, delipidised in chloroform and partially hydrolysed in 95% ethanol. To ensure the integrity of tissue mRNA, all further steps were carried out in autoclaved solutions containing distilled water treated for 12 h with 0.1% of the ribonuclease inhibitor diethyl pyrocarbonate. 17 The oligonucleotide probes complementary to the human m1 and m2 receptor gene were 3Ј-tail labelled with [
35 S]dATP using terminal deoxynucleotidyl transferase and purified according to the methodology provided. The labelled probe was added to standard hybridisation buffer at a final concentration of 1 × 10 6 dpm per 50 l. To hybridise the oligonucleotide probes to mRNA, 400 l of buffer-probe solution was added to each section, sealed with a wax coverslip and incubated in a humidity chamber at 37°C for 20-24 h. In addition, hybridisation controls were employed to ensure the specificity of oligonucleotide probe hybridisation. First, hybridisation was carried out using sections treated with 20 g ml −1 of RNAase A solution in 2 × saline sodium citrate (SSC) at 37°C for 30 min. Second, hybridisation was carried out in the presence of excess unlabelled probe. Post-hybridisation washes were in SSC at 25°C for 1 min, SSC with 50% formamide at 45°C for 4 × 15 min, and 0.5 × SSC at 25°C for 30 min. All sections were dipped in distilled water, followed by 70% ethanol. 
Data analysis
All statistical analysis was completed using Minitab computer software. The distribution of all parameters for the schizophrenic and control subjects was assessed using the Ryan-Joiner Normality Test and shown not to be significantly different to a normal distribution. Hence, ISHH, age, tissue pH, and PMI between groups were compared using the Student's t-test. Relationships between ISHH, age, DOI, final recorded antipsychotic drug dose, tissue pH, and PMI were assessed using Pearson Product-Moment correlation coefficient using an assumed straight line model. An analysis of covariance was also carried out to determine if age, PMI, pH, FDD, or DOI were confounding variables influencing the apparent relationship between radioligand binding data from the schizophrenic and control subjects.
